Showing 21 - 40 results of 136 for search '"Yale Cancer Center"', query time: 0.10s Refine Results
  1. 21
    Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial

    Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial by Kristina A. Fanucci, Yalai Bai, Vasiliki Pelekanou, Zeina A. Nahleh, Saba Shafi, Sneha Burela, William E. Barlow, Priyanka Sharma, Alastair M. Thompson, Andrew K. Godwin, David L. Rimm, Gabriel N. Hortobagyi, Yihan Liu, Leona Wang, Wei Wei, Lajos Pusztai, Kim R. M. Blenman

    Published 2023-05-01
    Get full text
    Article
  2. 22
    Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation

    Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation by Wesley L Cai, Jocelyn Fang-Yi Chen, Huacui Chen, Emily Wingrove, Sarah J Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Minghui Zhao, Amer Balabaki, Wenxue Li, Xufen Yu, Ethan D Krop, Yali Dou, Yansheng Liu, Jian Jin, Thomas F Westbrook, Don X Nguyen, Qin Yan

    Published 2022-08-01
    Get full text
    Article
  3. 23
    Leukocyte–Cancer Cell Fusion—Genesis of a Deadly Journey

    Leukocyte–Cancer Cell Fusion—Genesis of a Deadly Journey by Greggory S. Laberge, Eric Duvall, Kay Haedicke, John Pawelek

    Published 2019-02-01
    Get full text
    Article
  4. 24
    The Current Understanding of and Treatment Paradigm for Newly-Diagnosed <i>TP53</i>-Mutated Acute Myeloid Leukemia

    The Current Understanding of and Treatment Paradigm for Newly-Diagnosed <i>TP53</i>-Mutated Acute Myeloid Leukemia by Rory M. Shallis, Maximilian Stahl, Jan Philipp Bewersdorf, Amer M. Zeidan

    Published 2021-12-01
    Get full text
    Article
  5. 25
    Targeting Innate Immunity to Treat Cancer

    Targeting Innate Immunity to Treat Cancer by Matthew Austin, Harriet Kluger

    Published 2020-09-01
    Get full text
    Article
  6. 26
    Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer

    Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer by Sally J. Adua, Anna Arnal-Estapé, Minghui Zhao, Bowen Qi, Zongzhi Z. Liu, Carolyn Kravitz, Heather Hulme, Nicole Strittmatter, Francesc López-Giráldez, Sampada Chande, Alexandra E. Albert, Mary-Ann Melnick, Bomiao Hu, Katerina Politi, Veronica Chiang, Nicola Colclough, Richard J. A. Goodwin, Darren Cross, Paul Smith, Don X. Nguyen

    Published 2022-12-01
    Get full text
    Article
  7. 27
    Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

    Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials by Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou

    Published 2023-11-01
    Get full text
    Article
  8. 28
    P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

    P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES by Amer M. Zeidan, Kate Perepezko, Tehseen Salimi, Terri Washington, Robert Epstein

    Published 2023-08-01
    Get full text
    Article
  9. 29
    Accelerating cancer without mutations

    Accelerating cancer without mutations by Douglas E Brash

    Published 2019-03-01
    Get full text
    Article
  10. 30
    Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

    Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer by Caterina Bartolacci, Cristina Andreani, Gonçalo Vale, Stefano Berto, Margherita Melegari, Anna Colleen Crouch, Dodge L. Baluya, George Kemble, Kurt Hodges, Jacqueline Starrett, Katerina Politi, Sandra L. Starnes, Daniele Lorenzini, Maria Gabriela Raso, Luisa M. Solis Soto, Carmen Behrens, Humam Kadara, Boning Gao, Ignacio I. Wistuba, John D. Minna, Jeffrey G. McDonald, Pier Paolo Scaglioni

    Published 2022-08-01
    Get full text
    Article
  11. 31
    Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas

    Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas by Priscilla K. Brastianos, Albert E. Kim, Anita Giobbie-Hurder, Eudocia Quant Lee, Nancy Wang, April F. Eichler, Ugonma Chukwueke, Deborah A. Forst, Isabel C. Arrillaga-Romany, Jorg Dietrich, Zachary Corbin, Jennifer Moliterno, Joachim Baehring, Michael White, Kevin W. Lou, Juliana Larson, Magali A. de Sauvage, Kathryn Evancic, Joana Mora, Naema Nayyar, Jay Loeffler, Kevin Oh, Helen A. Shih, William T. Curry, Daniel P. Cahill, Fred G. Barker, Elizabeth R. Gerstner, Sandro Santagata

    Published 2022-03-01
    Get full text
    Article
  12. 32
    Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer

    Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer by Alexander Y. Deneka, Margret B. Einarson, John Bennett, Anna S. Nikonova, Mohamed Elmekawy, Yan Zhou, Jong Woo Lee, Barbara A. Burtness, Erica A. Golemis

    Published 2020-01-01
    Get full text
    Article
  13. 33
    PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)

    PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES... by Amer M. Zeidan, Karen Mosher, Sonia Souza, Beloo Mirakhur, Harold Keer, Jason Taylor

    Published 2023-08-01
    Get full text
    Article
  14. 34
    Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis

    Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis by Mingli Li, Lu Yang, Anthony K. N. Chan, Sheela Pangeni Pokharel, Qiao Liu, Nicole Mattson, Xiaobao Xu, Wen‐Han Chang, Kazuya Miyashita, Priyanka Singh, Leisi Zhang, Maggie Li, Jun Wu, Jinhui Wang, Bryan Chen, Lai N. Chan, Jaewoong Lee, Xu Hannah Zhang, Steven T. Rosen, Markus Müschen, Jun Qi, Jianjun Chen, Kevin Hiom, Alexander J. R. Bishop, Chun‐Wei Chen

    Published 2023-06-01
    Get full text
    Article
  15. 35
    1486 DDR1 expression is associated with a worse prognosis in intrahepatic cholangiocarcinoma

    1486 DDR1 expression is associated with a worse prognosis in intrahepatic cholangiocarcinoma by Xinwei Sher, Guy T Clifton, Joseph P Eder, Amy Mueller, Laura A Dillon, Thomas Schuerpf, Lawrence N Kwong

    Published 2023-11-01
    Article
  16. 36
    P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)

    P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA) by Amer M. Zeidan, Leyla Hernandez- Donoso, Sejla Hodzic, Henry Owusu, Dhrubajyoti Pathak, Summera Zhou, Eytan Stein

    Published 2023-08-01
    Get full text
    Article
  17. 37
    PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES

    PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES by A. Zeidan, V. Divino, M. DeKoven, D. Shah, E. Wang, D. Bey, T. Salimi, R. Epstein

    Published 2022-06-01
    Get full text
    Article
  18. 38
    Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade

    Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade by Ioannis A. Vathiotis, Leonidas Salichos, Sandra Martinez-Morilla, Niki Gavrielatou, Thazin Nwe Aung, Saba Shafi, Pok Fai Wong, Shlomit Jessel, Harriet M. Kluger, Konstantinos N. Syrigos, Sarah Warren, Mark Gerstein, David L. Rimm

    Published 2022-12-01
    Get full text
    Article
  19. 39
    714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors

    714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metast... by Mario Sznol, Adil Daud, Scott M Turner, Chris N Barnes, Susan Owen, Eric A Lefebvre, Hardean E Achneck

    Published 2023-11-01
    Article
  20. 40
    CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment

    CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment by Rui Han, Rui Han, Rui Han, Rui Han, Rui Han, Jiayin Li, Jing Hony, Jing Hony, Zhiwei Xiao, Jinghui wang, Man Yao, Man Yao, Shufang Liang, Shufang Liang, Lingeng Lu, Lingeng Lu, Lingeng Lu

    Published 2023-03-01
    Get full text
    Article

Search Tools: